Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: Impact of patient characteristics and timing of transplant

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 96-102

  Spina, Francesco ^a,b   Alessandrino, Paolo Emilio ^c   Milani, Raffaella ^a   Bonifazi, Francesca ^d   Bernardi, Massimo ^e   Luksch, Roberto ^a   Fagioli, Franca ^f   Formica, Chiara ^a,b   Farina, Lucia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Myelodysplastic syndromes; Therapy related

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RISK; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DONOR; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC RISK; HUMAN; LEUKEMIA RELAPSE; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; AGED; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RADIOTHERAPY; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855422191     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.603445     Document Type: Article

References (25)

1. B running RD, Matutes E, Harris NL, et al. Acute myeloid leukaemia: introduction. In: Jaff e ES, Harris NL, Stein H, et al., editors. World Health Organization classifi cation of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 77 - 80, 89 - 91.
2. E llis M, Ravid M, Lishner M. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 1993;11:9-13. (Pubitemid 23287046)
3. L eone G, Voso MT, Sica S, et al. Th erapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001;41: 255-276. (Pubitemid 32499409)
4. M auritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-2378.
5. S mith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52. (Pubitemid 36759634)
6. Olney HJ, Mitelman F, Johansson B, et al. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:413-423. (Pubitemid 34208802)
7. Bloomfi eld CD, Archer KJ, Mrzek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:362-378. (Pubitemid 34208798)
8. Witherspoon RP, Deeg HJ, Storer B, et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001;19:2134-2141. (Pubitemid 32372322)
9. L itzow MR, Tarima S, Prez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010;115:1850-1857.
10. G rimwade D, Walker H, Oliver F, et al. Th e importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Th e Medical Research Council Adult and Children ' s Leukaemia Working Parties. Blood 1998;92:2322-2333. (Pubitemid 28452973)
11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Th erapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649. (Pubitemid 46594039)
12. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specifi c comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919. (Pubitemid 41510773)
13. P rzepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GvHD grading. Bone Marrow Transplant 1995;15:825-828.
14. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute GvHD: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-864. (Pubitemid 27321388)
15. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graftversus- host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217. (Pubitemid 10036817)
16. G ray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1140-1154.
17. Krger N, Brand R, van Biezen A, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009;94:542-549.
18. d e Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110:620-630.
19. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-125. (Pubitemid 38159447)
20. Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapyrelated acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22:2510-2511. (Pubitemid 41115412)
21. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007;13:655-664. (Pubitemid 46767993)
22. Schlenk RF, Dner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with highrisk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010;28:4642-4648.
23. Alatrash G, de Lima M, Hamerschlak N, et al. Myeloablative reduced-toxicity i.v. busulfan-fl udarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011 Feb 18. [Epub ahead of print]
24. T allman MS, Rowlings PA, Milone G, et al. Eff ect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in fi rst complete remission. Blood 2000;96:1254-1258. (Pubitemid 30658451)
25. M eyer E, Beyersmann J, Bertz H, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant 2007;39:173-178. (Pubitemid 46178752)